Salvianolic acid B decreases interleukin-1β-induced colitis recurrence in mice
Open Access
- 20 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Chinese Medical Journal
- Vol. 133 (12), 1436-1444
- https://doi.org/10.1097/CM9.0000000000000773
Abstract
Background Degree of mucosal recovery is an important indicator for evaluating the therapeutic effects of drugs in treatment of inflammatory bowel disease (IBD). Increasing evidences has proved that tight junction (TJ) barrier dysfunction is one of the pathological mechanisms of IBD. The aim of this study was to observe whether enhancement of TJ can decrease colitis recurrence. Methods Eighty C57BL/6 mice were randomly divided into four groups including normal group, colitis group, sulfasalazine (SASP) treated group, and traditional Chinese drug salvianolic acid B (Sal B) treated group. Colitis was established in mice by free drinking water containing dextran sulfate sodium, after treatments by SASP and Sal B, recombinant human interleukin-1 beta (IL-1 beta) was injected intraperitoneally to induce colitis recurrence. Results Compared with sham control, cell apoptosis in colitis group was increased from 100.85 +/- 3.46% to 162.89 +/- 11.45% (P = 0.0038), and TJ dysfunction marker myosin light chain kinase (MLCK) was also significantly increased from 99.70 +/- 9.29% to 296.23 +/- 30.78% (P = 0.0025). The increased cell apoptosis was reversed by both SASP (125.99 +/- 8.45%vs.162.89 +/- 11.45%,P = 0.0059) and Sal B (104.27 +/- 6.09%vs.162.89 +/- 11.45%,P = 0.0044). High MLCK expression in colitis group was reversed by Sal B (182.44 +/- 89.42%vs.296.23 +/- 30.78%,P = 0.0028) but not influenced by SASP (285.23 +/- 41.04%vs.296.23 +/- 30.78%,P > 0.05). The recurrence rate induced by recombinant human IL-1 beta in Sal B-treated group was significantly lower than that in SASP-treated group. Conclusions These results suggested a link between intestinal mucosal barrier dysfunction, especially TJ barrier dysfunction, and colitis recurrence. The TJ barrier dysfunction in remission stage of colitis increased the colitis recurrence. This study might provide potential treatment strategies for IBD recurrence.Keywords
This publication has 28 references indexed in Scilit:
- Oral administration of the flavonoid myricitrin prevents dextran sulfate sodium-induced experimental colitis in mice through modulation of PI3K/Akt signaling pathwayMolecular Nutrition & Food Research, 2013
- Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studiesInflammatory Bowel Diseases, 2012
- Dietary intervention with narrow-leaved cattail rhizome flour (Typha angustifolia L.) prevents intestinal inflammation in the trinitrobenzenesulphonic acid model of rat colitisBMC Complementary and Alternative Medicine, 2012
- The Epithelial Barrier Is Maintained by In Vivo Tight Junction Expansion During Pathologic Intestinal Epithelial SheddingGastroenterology, 2011
- MLCK-dependent exchange and actin binding region-dependent anchoring of ZO-1 regulate tight junction barrier functionProceedings of the National Academy of Sciences, 2010
- Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depressionJCI Insight, 2008
- Accelerated Ulcer Healing and Resistance to Ulcer Recurrence with Gastroprotectants in Rat Model of Acetic Acid-induced Gastric UlcerJournal of Clinical Biochemistry and Nutrition, 2008
- Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivoJCI Insight, 2006
- Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivoJCI Insight, 2005
- Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD)Clinical and Experimental Immunology, 1995